Literature DB >> 6113910

Dose-response studies of quazepam.

A Kales, M B Scharf, E O Bixler, P K Schweitzer, J A Jacoby, C R Soldatos.   

Abstract

Quazepam, an investigational benzodiazepine, was evaluated in doses of 7.5, 15, and 30 mg in a 12-night protocol including four nights of drug trial. All three doses were effective in inducing and maintaining sleep, with the highest degree of effectiveness after the first drug night. Carry-over effectiveness, which was seen after withdrawal of all three doses, persisted throughout the withdrawal period after the 30-mg dose. Quazepam's effects during both drug use and withdrawal appeared to be dose related; 15 mg induced a greater reduction in wake time after sleep onset than the 7.5-mg dose, and 30 mg induced even greater differences in both wake time after sleep onset and total wake time. Subjective reports of improved sleep were in general agreement with the objective data at each dose level. Side effects appeared to be dose related in terms of severity. The efficacy and comparatively less severe side effects of the 7.5- and 15-mg doses of quazepam suggest that these doses may be optimal when the drug is considered for the adjunctive treatment of insomnia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113910     DOI: 10.1038/clpt.1981.148

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

Review 1.  Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia.

Authors:  S I Ankier; K L Goa
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

2.  Overestimations of hypnotic drug effects by insomniacs--a hypothesis.

Authors:  D Schneider-Helmert
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.